NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab for the treatment of r/r cHL

 NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab for the treatment of r/r cHL

NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab for the treatment of r/r cHL

Shots:
  •  Boehringer Ingelheim (BI) and BeiGene are in collaboration since 2013 for the development of tislelizumab
  • BI BioXcellence is providing CMC services and also helping BeiGene with process & analytical method, supply of GMP clinical material, and CMC filing support with the NMPA
  • Boehringer claims to provide manufacturing support to BeiGene for tislelizumab for global market, if approved in china
Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image:  PR news wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post